N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Clinical Investigation to Validate the Safety and Performance of the ABLE Kids Device in Pediatric Patients With Neurological Gait Disorders in a Clinical Setting

Sponsor: ABLE Human Motion S.L. • ClinicalTrials.gov ID: NCT07745712

Registry updated: 2026-09-08
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The primary objective of the study is to validate the safety and clinical performance of the ABLE Kids device in pediatric patients with neurological gait disorders or muscular weakness during a 10-session gait training program in a clinical setting. The secondary objective of the study focuses on obtaining preliminary data on the potential clinical and psychosocial benefits of the product.

Interventions

  • ABLE Kids (Device)
    Participants will undergo a 10-session gait training program with the exoskeleton, five times a week for up to 3 weeks. Each session will last 60 minutes.

Eligibility criteria

Inclusion Criteria: * Minors with gait impairments, ranging from mild to severe, resulting from neurological conditions or muscular weakness * Anthropometric measurements compatible with the use of the exoskeleton, particularly: * Weight under 75 kg * Height between 1.0-1.5 m * Hip: maximum distance between greater trochanters of 35 cm * Thigh: maximum distance from trochanter to knee joint line of 36 cm * Lower leg: maximum distance from knee joint line to shoe sole of 45 cm * Medically stable * Intact skin in areas in contact with the device * Favorable medical assessment for standing, gait training, and weight-bearing activities * Signed informed consent from parents or legal guardians, and assent from the minor whenever possible, according to age and cognitive ability Exclusion Criteria: * Severe spasticity in the lower limbs (Modified Ashworth Scale \[MAS\] \> 3) * Severe osteoporosis resulting in atraumatic bone fractures * Unhealed fractures or history of fragility fractures in the lower extremities within the past 2 years * Unstable or painful hip dislocation (Migration Percentage \[MP\] \> 50%) * Symptomatic heterotopic ossification with mechanical limitation or pain * Anatomical limitations incompatible with proper fitting and safe use of the device: * Leg length discrepancy \>1.5 cm in the upper segment or \>2.0 cm in the lower segment * Severe scoliosis (Cobb angle \>40° without the possibility of orthotic use during operation) * Inability to achieve proper adjustment within the device * Joint range of motion limitations preventing use of the exoskeleton: * Knee flexion contracture ≥40° * Hip flexion contracture ≥20° * Rigid equinus foot * Spine or lower extremity surgery within the last 3 months * Recently implanted pacemakers * Inability to communicate pain, fear, or discomfort (verbally or nonverbally) * Daytime mechanical ventilation * Uncontrolled epileptic seizures * Medical or cardiovascular instability * Considered unsuitable by physicians and physiotherapists. Any acute medical condition such as fever, infection, respiratory problems, urinary symptoms, uncontrolled pain, new swelling or redness in the extremities, active deep vein thrombosis, or severe comorbidities considered incompatible with the use of ABLE Kids until clinical resolution * Absence of head or trunk control in sitting or standing that cannot be compensated through the use of orthotic support during exoskeleton use

Conditions

Gait Impairment Cerebral Palsy (CP) Neuromuscular Diseases (NMD) Spinal Cord Injuries (SCI) Spina Bifida Muscular Weakness Acquired Brain Injury (Including Stroke)

Locations

  • Som·hi Rehab — Girona, Girona, Spain
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record